Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 September 2020 | Story Andre Damons | Photo Pexels

Researchers from the University of the Free State (UFS) and the Central University of Technology (CUT) have recently learned that their research projects will be funded, with one research project even getting double the amount of funding requested. 

The research project of Dr Doors Fonternel, an MMed student working under Dr Edwin Turton in the Department of Anaesthesiology at the UFS, and Prof Ihar Yadroitsau (Igor Yadroitsev), Research Chair in Medical Product Development through Additive Manufacturing and the Faculty of Engineering, Built Environment and Information Technology at CUT, titled 3D Printed laryngoscope for endotracheal intubation, received R400 000 in funding. The project only requested half the amount, but in granting the funding, the evaluation committee was of the opinion that due to the relevance of the research and the long-term sustainability of the project, funding should be adjusted to R400 000.  

Another research project receiving R400 000 in funding, is a project by Dr Alice Brink, Senior Lecturer in the Department of Chemistry at the UFS, and Dr Tshepiso J Makhafola, Assistant Dean: Research, Innovation and Engagement and Senior Lecturer: Clinical Technology in the Faculty of Health and Environmental Sciences at CUT. The committee supported the novelty of the project and the contribution towards both applicants’ participation in the Future Professors’ Programme.
These projects are part of nine collaboration projects between researchers from the UFS and CUT that were approved for funding between 2019 and 2020. The funding ranges from R50 000 to R400 000. 

Using 3D printer technology 

Dr Fonternel says getting more funding than expected gives them the motivation to push through the obstacles presented by a project like this. 

“It is innovative and uncharted, so it helps to know that others also believe in the possibilities. Apart from the design, testing, and validation that this project aims to achieve, we are looking to broaden the scope into materials and sterilisation. We are also looking at acquiring equipment to enable the UFS to be able to design and manufacture devices of similar need and purpose,” says Dr Fonternel.

According to Dr Fonternel, who designed, developed, and then prototyped the video laryngoscope with the help of the Product Development and Testing Station (PDTS) at CUT, he hopes that with this new research, the validated technology of video laryngoscopy could be provided to a much larger medical community.

Prof Yadroitsau’s role is the overall project management, mechanical testing, project analysis, and possible additional fundraising.

“This can be beneficial to rural hospitals and centres with limited funds and equipment and can make a difference in the quality of care we provide to our patients. It has the potential to improve the safety of patients and healthcare workers in our current COVID-19 battle by bringing First World technology to the front line.” 

Valuable contribution to cancer research

Drs Brink and Makhafola will be collaborating on the development and testing of organometallic complexes, primarily model pharmaceuticals that can carry a radioactive metal centre. Their collaboration will develop model lead compounds and then test their biological activity, particularly for anticancer and antimicrobial activities, including toxicological profiling to determine if it is a viable option for future cancer treatment. 

“Drug development has significant challenges, particularly for academic institutions that do not have access to the focused and integrated specialty networks as developed by Big Pharma such as Roche, Novartis, Bayer, etc.  The research and development pathway of a new pharmaceutical agent that becomes commercially available, takes on average 12 years and costs approximately £1,15 bn.”

“For every single drug that receives approval, an estimated 10 000 compounds have been considered as viable options but have failed for one reason or another. Our research collaboration focuses on addressing these two main challenges that hinder academia from successfully entering the drug market.  We hope to identify potential lead compounds with novel mechanisms of action for the development of cancer therapeutics,” says Dr Brink.

This collaborative team hopes to promote and make a valuable contribution to cancer research, specifically towards the discovery of new effective cancer treatments/drugs. 

New ways of imaging patients with rheumatoid arthritis

Dr Evbuomwan Osayande, a nuclear medicine specialist at the UFS/Universitas Academic Hospital, says his research will compare the efficacy of EC-DG (ethylenedicysteine-deoxyglucose) imaging with ultrasound imaging in patients with rheumatoid arthritis. At this stage, the research is still in the protocol phase. A protocol has been submitted to the Health Sciences Research Ethics Committee of the UFS for approval. The project received R350 000. 

“If this imaging modality proves to be highly accurate and can detect disease activity, including low disease activity, much earlier than other investigational tools, it might become a routine imaging modality in the management of patients with rheumatoid arthritis,” says Dr Osayande, the principal investigator in this research.

If we can detect low disease activity with the EC-DG imaging, says Dr Osayande, it will ensure that the rheumatologists will continue patient treatment and thus prevent them from having complications, such as bone erosions and joint destruction. “It is an exciting project and we are all looking forward to the outcome.”

Embracing 4IR

The research project of Dr Thuthukile Jita, Senior Lecturer in the UFS School of Education Studies, and Dr Carlie Luzaan Schlebusch from CUT, investigates the possibilities and affordances of training student teachers to embrace the Fourth Industrial Revolution, specifically by learning to teach Science in schools using mobile devices and mobile apps. The project received R50 000 in funding.

“The study is perfectly timed amid the COVID-19 pandemic, which has resulted in large-scale disruption of schooling as we know it.  The call for teachers and learners and the education system generally to embrace technology and use information and communication technology (ICT) to continue and restore teaching and learning in some way, has been overwhelming.” 

“Consequently, there has been an almost overnight surge in the use of mobile devices for teaching and learning in schools. Sadly, the pandemic has further exposed the digital-divide reality that not all schools, teachers, and/or learners are able to engage effectively with the technology.” 

“Therefore, this study will assist in repositioning teacher preparation to use mobile devices and applications that are relevant for the topics covered in the national Curriculum and Assessment Policy Statement (CAPS) document, starting with the subject Natural Sciences for the senior phase, which include Grades 7 to 9,” says Dr Jita, who is the principal investigator of the project and who is also responsible for the conceptualisation and overall direction of the project milestones.

Research projects that have also received funding, include: 

• IoT-based early diagnostics of mobility challenges in the elderly by Elisha Markus (CUT) and Paul Kogeda (UFS). 
• Impact of urban development on environmental sustainability: Case study of Mangaung Metropolitan municipality by Dr SA Oke (CUT) and Dr Olusola Ololade (UFS).
• Promoting inclusive pedagogies through transformative learning modalities in multicultural educational settings by Dr June Palmer (CUT) and Dr Rantsie Kgothule (UFS).
• Optimisation of imaging protocols for maxillofacial reconstructive prosthesis design and modelling by Prof Deon de Beer (CUT) and Dr Jacques Janse van Rensburg (UFS).
• LET-MI-C project (Lumbar ErecTor spinae block spread using MRI and CT) by Dr Je’nine Horn-Lodewyk (CUT) and Prof Gillian Lamacraft (UFS).  

News Archive

Research contributes to improving quality of life for cancer patients
2016-11-21

Description: Inorganic Chemistry supervisors  Tags: Inorganic Chemistry supervisors

Inorganic Chemistry supervisors in the Radiopharmacy
Laboratory during the preparation of a typical complex
mixture to see how fast it reacts. Here are, from the left,
front: Dr Marietjie Schutte-Smith, Dr Alice Brink
(both scholars from the UFS Prestige
Scholar Programme), and Dr Truidie Venter (all three
are Thuthuka-funded researchers).
Back: Prof André Roodt and Dr Johan Venter.
Photo: Supplied

Imagine that you have been diagnosed with bone cancer and only have six months to live. You are in a wheelchair because the pain in your legs is so immense that you can’t walk anymore – similar to a mechanism eating your bones from the inside.

You are lucky though, since you could be injected with a drug to control the pain so effective that you will be able to get out of the wheelchair within a day-and-a-half and be able to walk again. Real-life incidents like these provide intense job satisfaction to Prof André Roodt, Head of Inorganic Chemistry at the University of the Free State (UFS). The research, which is conducted by the Inorganic Group at the UFS, contributes greatly to the availability of pain therapy that does not involve drugs, but improves the quality of life for cancer patients.

The research conducted by the Inorganic Group under the leadership of Prof Roodt, plays a major role in the clever design of model medicines to better detect and treat cancer.

The Department of Chemistry is one of approximately 10 institutions worldwide that conducts research on chemical mechanisms to identify and control cancer. “The fact that we are able to cooperate with the Departments of Nuclear Medicine and Medical Physics at the UFS, the Animal Research Centre, and other collaborators in South Africa and abroad, but especially the methodology we utilise to conduct research (studying the chemical manner in which drugs are absorbed in cancer as well as the time involved), enhances the possibility of making a contribution to cancer research,” says Prof Roodt.

Technique to detect cancer spots on bone
According to the professor, there are various ways of detecting cancer in the body. Cancer can, inter alia, be identified by analysing blood, X-rays (external) or through an internal technique where the patient is injected with a radioactive isotope.

Prof Roodt explains: “The doctor suspects that the patient has bone cancer and injects the person with a drug consisting of an isotope (only emits X-rays and does no damage to tissue) that is connected to a phosphonate (similar to those used for osteoporosis). Once the drug is injected, the isotope (Technetium-99m) moves to the spot on the bone where the cancer is located. The gamma rays in the isotope illuminate the area and the doctor can see exactly where treatment should be applied. The Technetium-99m has the same intensity gamma rays as normal X-rays and therefore operates the same as an internal X-ray supply.” With this technique, the doctor can see where the cancer spots are within a few hours.

The same technique can be used to identify inactive parts of the brain in Alzheimer patients, as well as areas of the heart where there is no blood supply or where the heart muscle is dead.

Therapeutic irradiation of cancer
For the treatment of pain connected with cancer, the isotope Rhenium-186 is injected. Similar to the manner in which the Technetium-99m phosphonate compound is ingested into the body, the Rhenium-186 phosphonate travels to the cancer spots. Patients thus receive therapeutic irradiation – a technique known as palliative therapy, which is excellent for treating pain. A dosage of this therapy usually lasts for about two months.

The therapy is, however, patient specific. The dosages should correspond with the occurrence and size of cancer spots in the patient’s body. First, the location of the cancer will be determined by means of a technetium scan. After that, the size of the area where the cancer occurs has to be determined. The dosage for addressing total pain distribution will be calculated according to these results.

Technique to detect cancer spots on soft tissue
Another technique to detect cancer as spots on bone or in soft tissue and organs throughout the body is by utilising a different type of irradiation, a so-called PET isotope. The Fluor-18 isotope is currently used widely, and in Pretoria a machine called a cyclotron was produced by Dr Gerdus Kemp, who is a former PhD graduate from the Inorganic Research Group. The F-18 is then hidden within a glucose molecule and a patient will be injected with the drug after being tranquillised and after the metabolism has been lowered considerably. The glucose, which is the ‘food' that cancer needs to grow, will then travel directly to the cancer area and the specific area where the cancer is located will thus be traced and ‘illuminated’ by the Fluor-18, which emits its own 'X-rays'.

In the late 80s, Prof Roodt did his own postdoctoral study on this research in the US. He started collaborating with the Department of Nuclear Medicine at the UFS in the early 90s, when he initiated testing for this research.

Through their research of more than 15 years, the Inorganic Group in the Department of Chemistry has made a major contribution to cancer research. Research on mechanisms for the detection of cancer, by designing new clever chemical agents, and the chemical ways in which these agents are taken up in the body, especially contributes to the development in terms of cancer therapy and imaging, and has been used by a number of hospitals in South Africa.

The future holds great promise
Prof Roodt and his team are already working on a bilateral study between the UFS and Kenya. It involves the linking of radio isotopes, as mentioned above, to known natural products (such as rooibos tea), which possess anti-cancer qualities.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept